Pfizer may look messy post-Upjohn spinoff, but better days could be ahead: analyst

Confronting generic pricing pressure that put a hard cap on profits, Pfizer's Upjohn spinoff deal with Mylan allowed both companies to reinvent themselves in the face of stagnant growth. The Pfizer left over after the merger could be a "messy" one, one analyst says, but brighter days should be on the horizon.